Navigation Links
Generex Provides Clarification of Facts
Date:6/27/2011

e on a comprehensive strategy to achieve FDA approval of Generex Oral-lyn™.  Today, Dr. Anderson, an independent member of the Generex Board, commented:  "The Company's scientific team is confident that our clinical and regulatory program is designed for success, and we intend to conduct a broader study to include a wider patient population in both type 1 and type 2 diabetes."  The full presentation from the annual meeting of stockholders' is available for viewing on the Generex website at www.generex.com.

Mark Fletcher, Generex President & Chief Executive Officer, stated:  "We have made great strides in establishing  a top notch scientific team at Generex and, as a result, have established a realistic and focused plan to realize success in the future for the largest possible patient population.  The closing of the current Phase III study and the data we obtain from it will further that effort.  Generex Oral-lyn™ has demonstrated efficacy and safety in all of the studies conducted to date."

The June 16 Generex press release stated that the Company's clinical and regulatory plan for Generex Oral-lyn™ will "focus on rapid registration in the North American major markets, with its rapid absorption and sharp peak in plasma insulin concentration mimicking normal insulin secretion, and Generex Oral-lyn™'s short duration of activity reducing the potential for hypoglycemia.  Studies will include a key activity/effect (pharmokinetic/glucodynamic) study using the final formulation and a series of small, well-designed phase 3 studies (potentially conducted as one study with multiple arms)."  Generex management anticipates that these studies will be completed during 2013.  Generex will also focus on studies that will measure Generex Oral-lyn™'s ability to provide metabolic benefits that cannot be achieved with subcutaneously inj
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces Results of Annual Stockholders Meeting
2. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
3. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
4. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
5. Generex Announces $3.0 Million Capital Investment
6. Generex Provides Additional Details for October 21st Live Video Webcast
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
10. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
11. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , November 21, 2014 , ... responsable comercial   Mariano Rodríguez es elegid ... KLOX está en marcha para comenzar de ... cura de heridas de reciente aprobación en Europa   , ... compañía") se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Author ... Short Walk to the Other Side” published as ... “Award-Winning Finalist in the “Fiction: Short Story” category of ... Jeffrey Keen, President and CEO of USA Book News, ... mainstream and independent publishers, including Simon & Schuster, Penguin, ...
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) and ... PCI, Inc., leading suppliers of ozone process technology ... to provide a new state-of-the-art ozone system for ... Wastewater Treatment. The new ozone disinfection system ... dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ozone ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... $1,036,024, or 89%, for the nine months ended September 30, ... ... 26 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai,Cactus Bio-tech Inc. (OTC Bulletin Board: CKGT), a ... filed its quarterly report on SEC Form 10QSB on November,19, 2007 and ...
... Dramatically Enhances the Way Ultrasound, Departments Work and Provides a ... ... Applications, CHICAGO, Nov. 26 At the 93rd Scientific ... from,Nov. 25 to 30 at McCormick Place (Booth 7713, Hall B), ...
... to Integrate with Multiple Disparate PACS and ... ... CHICAGO, Nov. 26 RSNA Booth #5924 -- ... and,interoperability between diagnostic acquisition devices, PACS, HIS, RIS,and related ...
Cached Biology Technology:China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 3China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 4Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 2Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 3Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 4Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 5Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 6E-Rad Solutions Selects Compressus' Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market 2E-Rad Solutions Selects Compressus' Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market 3
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/7/2014)... Leading Biometric companies aim to provide ... online transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Google Inc. (NASDAQ: GOOG ), Microsoft ... EBAY ) and MasterCard Inc. (NYSE: MA) ... biometric authentication company focused on the growing mobile commerce is ...
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... Federation of American Societies for Experimental Biology (FASEB) announces ... (SRC): Mobile DNA in Mammalian Genomes. Mobile elements ... the structure and altering functions within mammalian genomes, and ... explore the explosion of data from high throughput sources, ...
... This release is available in French . ... on the brain,s ability to be plastic that is to ... study from the Montreal Neurological Institute The Neuro, McGill University, ... nervous system known as netrin, plays a key role in regulating ...
... defines and names groups of organisms is a ... methods used during the beginnings of the discipline in ... information to delineate new species, the study of the ... of taxonomists. These studies often require first-hand examination of ...
Cached Biology News:Finding the way to memory 2Finding the way to memory 3Biodiversity exploration in the 3-D era 2
Similar to proteasome (prosome, macropain) 26S subunit, ATPase, 1 Antigen: Recombinant Protein...
RABBIT ANTI AMPHOTERIN...
See product name for description....
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
Biology Products: